Where depression treatment is heading
Major depressive disorder · Updated Nov 12, 2026
Antidepressants and therapy help most people, but about a third do not recover after two medicines. Two psychedelics had positive late-stage trials in 2026, and several pills with new mechanisms are in large trials.
- 791studies open or running
- 55of them in phase 3
- 4,075papers published this year
- 155NIH-funded projects
-
Now
Nov 2026
Psilocybin positive in two large trialsHappened
In depression that had not responded to two antidepressants, with benefit lasting at least 26 weeks.
LSD-based drug positive in depressionHappened
A single supervised dose of DT120 met its goal in a phase 3 trial.
-
6 months
by May 2027
Psilocybin application completedLikely
The final part of the FDA filing is expected in late 2026, starting the review.
Seltorexant add-on resultPossible
A pill that blocks a wakefulness signal, for depression with insomnia, in 752 people. The trial finishes in December 2026.
Azetukalner first phase 3 resultPossible
An epilepsy-research drug tested alone in 450 people; the trial is fully enrolled.
-
12 months
by Nov 2027
FDA decision on psilocybinPossible
The company is planning for a launch in the first half of 2027. That needs approval and a change in the drug's legal status.
A second psilocybin-type drug reportsPossible
CYB003 in 330 people finishes in June 2027.
Osavampator add-on resultsPossible
A pill acting on the brain's glutamate system, added to an antidepressant, in two 200-person trials.
-
3 years
by late 2029
Brenipatide phase 3 resultLikely
A Lilly drug tested in 1,000 people, finishing in February 2028.
Seltorexant on its ownPossible
A 600-person trial without another antidepressant finishes in August 2028.
Psychedelic treatment in clinicsPossible
Supervised dosing sessions available through certified centers.
-
5 years
by late 2031
Does esketamine prevent suicide attempts?Possible
A trial in 258 people finishes in 2031.
Choosing treatment by brain testLong shot
NIH-funded work aims to match people to treatments using measures of thinking and brain activity.
The research paths
Psychedelics
Details and 2 trialsHide
One or two supervised doses with effects lasting months. Psilocybin is closest to an FDA decision.
WatchThe FDA review, and how treatment centers would be set up.
Pills with new mechanisms
Details and 4 trialsHide
Daily pills that do not act on serotonin: a potassium-channel opener, a glutamate modulator, and a Lilly drug in two 1,000-person trials.
WatchAzetukalner, the first to report.
Depression with poor sleep
Details and 2 trialsHide
Seltorexant blocks orexin, the signal that keeps the brain awake, aiming at people whose depression comes with insomnia.
WatchWhether mood improves beyond what better sleep explains.
Matching people to treatments
Details and 1 trialsHide
Using a test to pick who gets which drug, in place of trial and error.
WatchALTO-300, which enrolls by a brain-wave marker.
Borrowed from other conditions
From Psychedelic research
Psilocybin
FDA filing under way
The active compound in "magic mushrooms", made to pharmaceutical standard.
From Epilepsy research
Azetukalner
Phase 3
Developed to calm overactive nerve cells in epilepsy, where mood improvements were noticed.
From Insomnia medicines
Seltorexant
Phase 3
From the same family as newer sleeping pills that block orexin.
From Sleepiness treatment
Solriamfetol
Phase 3
A wakefulness drug for sleep apnea and narcolepsy, tested for depression with excessive sleepiness.
From Anesthesia
Esketamine
Approved; new use in phase 3
A form of the anesthetic ketamine, already approved as a nasal spray, now tested for reducing suicide attempts.
Open to join now
-
Depression with insomnia
Seltorexant added to an antidepressant
Locations and eligibility → -
Major depression
Brenipatide (RENEW-MDD-1)
Locations and eligibility → -
Depression on an antidepressant
CYB003, a psilocybin-type drug
Locations and eligibility → -
Depression not controlled
Lumateperone add-on
Locations and eligibility → -
Major depression
Osavampator add-on, maintenance
Locations and eligibility → -
Depression with insomnia
Seltorexant on its own
Locations and eligibility →
See every recruiting depression trial →
When the large trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
Knowledge on the way
Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.
- AreaQuestionFunded throughNews likely
- Detection Tests of thinking that predict which treatment will workStanford University · NIH Funded through Feb 2029 News likely 2027–2029
- Causes Why ketamine-type drugs work fast, and how to make it lastNIH mental health institute staff scientists Funded through Ongoing News likely Continuous
- Risk Stress response in the brain and suicide riskNew York State Psychiatric Institute · NIH Funded through Jul 2031 News likely 2029–2031
What just happened
Psilocybin benefit held at 26 weeks
Follow-up of the second phase 3 trial.
LSD-based DT120 positive in depression
Top-line result from the Emerge trial.
Second psilocybin phase 3 trial positive
Two doses three weeks apart beat a 1 mg dose at week 6.
Standard treatment today
- First treatmentTalk therapy, an antidepressant, or both.
- Not better after one medicineSwitch, raise the dose, or add a second medicine such as an atypical antipsychotic.
- Not better after twoEsketamine nasal spray, transcranial magnetic stimulation or electroconvulsive therapy.
How to read this page, and sourcesHow to read this page, and sources
- Psilocybin was tested in depression that had not responded to two medicines, not in depression generally.
- In psychedelic trials most people can tell whether they got the drug, which can inflate the measured benefit.
- Completion dates are what each trial registered. Results usually follow 3 to 12 months later.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See depression trials recruiting now →